Home LiteratureArticle Details
PMID: 16177390 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Relationship of virulence factor expression to evolved virulence in mouse-passaged Cryptococcus neoformans lines.

Infection and immunity ·Vol. 73 ·No. 10 ·2005-10-00 ·Pages 7047-50

McClelland EE, Perrine WT, Potts WK, Casadevall A

Abstract

Serial passage of Cryptococcus neoformans in mice increases virulence relative to the nonpassaged line. Postpassaged lines showed no difference in the expression of most known virulence factors, with the exception that the more virulent lines had smaller capsules in vitro. These data imply that other mechanisms of virulence remain to be discovered.

MeSH Terms
Animals Cryptococcus neoformans/growth & development,pathogenicity Mice Serial Passage Virulence Virulence Factors/metabolism
Chemicals
Virulence Factors
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
McClelland Erin E
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA. mcclella@aecom.yu.edu
Perrine Wesley T
Potts Wayne K
Casadevall Arturo
References (24)
24 references, click to expand
  1. Monoclonal antibody based ELISAs for cryptococcal polysaccharide.
    J Immunol Methods. 1992 Sep 18;154(1):27-35 PMID: 1401941
  2. Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans.
    Infect Immun. 1987 Aug;55(8):1751-4 PMID: 3112009
  3. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans.
    Mol Microbiol. 2001 Jan;39(1):166-75 PMID: 11123698
  4. Genetic resistance to murine cryptococcosis: the beige mutation (Chédiak-Higashi syndrome) in mice.
    Infect Immun. 1985 Jan;47(1):288-93 PMID: 3965401
  5. Lipid peroxidation by alveolar macrophages challenged with Cryptococcus neoformans, Candida albicans or Aspergillus fumigatus.
    Med Mycol. 2000 Dec;38(6):443-9 PMID: 11204882
  6. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes.
    Infect Immun. 1998 Jan;66(1):89-97 PMID: 9423844
  7. Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages.
    Infect Immun. 1999 Nov;67(11):6034-9 PMID: 10531264
  8. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Infect Immun. 1995 Aug;63(8):3005-14 PMID: 7622223
  9. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans.
    J Exp Med. 1996 Aug 1;184(2):377-86 PMID: 8760791
  10. Urease as a virulence factor in experimental cryptococcosis.
    Infect Immun. 2000 Feb;68(2):443-8 PMID: 10639402
  11. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S436-9 PMID: 3055212
  12. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule.
    J Immunol. 2001 Apr 1;166(7):4620-6 PMID: 11254720
  13. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils.
    Infect Immun. 1996 Aug;64(8):2897-903 PMID: 8757810
  14. Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans.
    Proc Biol Sci. 2004 Aug 7;271(1548):1557-64 PMID: 15306300
  15. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation.
    Infect Immun. 1995 Mar;63(3):770-8 PMID: 7868246
  16. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2).
    Infect Immun. 2003 Nov;71(11):6155-64 PMID: 14573631
  17. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.
    Infect Immun. 1986 Jan;51(1):218-23 PMID: 3079732
  18. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
    J Immunol. 2001 Feb 1;166(3):2100-7 PMID: 11160261
  19. Apoptosis induction by glucuronoxylomannan of Cryptococcus neoformans.
    Med Mycol. 2003 Aug;41(4):347-53 PMID: 12964728
  20. Experimental evolution of parasites.
    Science. 1998 Nov 20;282(5393):1432-5 PMID: 9822369
  21. [Comparative study of two culture media for the detection of phospholipase activity of Candida albicans and Cryptococcus neoformans strains].
    Rev Iberoam Micol. 2002 Jun;19(2):95-8 PMID: 12828511
  22. Cryptococcus neoformans melanin and virulence: mechanism of action.
    Infect Immun. 1995 Aug;63(8):3131-6 PMID: 7622240
  23. Cryptococcus neoformans. I. Nonencapsulated mutants.
    J Bacteriol. 1967 Nov;94(5):1475-9 PMID: 6057803
  24. Characterization of a phenol oxidase from Cryptococcus neoformans var. neoformans.
    Microbiol Immunol. 1993;37(10):759-64 PMID: 8289682
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/IAI.73.10.7047-7050.2005
Email
mcclella@aecom.yu.edu
Published
2005-10-00
Pages
7047-50
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC1230917
Subset
IM
Grants
NIAID NIH HHS · R01 AI033142 · United States
NIGMS NIH HHS · GM-39578 · United States
NIGMS NIH HHS · R01 GM039578 · United States
NIGMS NIH HHS · R21 GM071421 · United States
NIAID NIH HHS · R01 AI033774 · United States
NHLBI NIH HHS · R01 HL059842 · United States
NIAID NIH HHS · AI033142 · United States
NIAID NIH HHS · AI033774 · United States
NHLBI NIH HHS · HL059842 · United States
NIAID NIH HHS · R01 AI052733 · United States
NIAID NIH HHS · AI052733 · United States
NIAID NIH HHS · R37 AI033142 · United States
NIGMS NIH HHS · GM-071421 · United States
External Links
PubMed source DOI: 10.1128/IAI.73.10.7047-7050.2005 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2